Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients
Date:
05/26/2022
Topics:
Citation:
Dioverti MV, Gaston DC, Morris CP, Huff CA, Jain T, Jones R, Anders V, Lederman H, Saunders J, Mostafa HH, Avery RK. Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients. Open Forum Infect Dis. 2022 May 26;9(6):ofac064. doi: 10.1093/ofid/ofac064. PMID: 35663288; PMCID: PMC9154336.
Abstract
Profoundly B-cell-depleted patients can have prolonged severe acute respiratory syndrome coronavirus 2 infections with evidence of active viral replication, due to inability to mount an adequate humoral response to clear the virus. We present 3 B-cell-depleted patients with prolonged coronavirus disease 2019 infection who were successfully treated with a combination of casirivimab/imdevimab and remdesivir.